Royal Bank Of Canada reiterated their hold rating on shares of Humana Inc. (NYSE:HUM) in a research note released on Tuesday. The brokerage currently has a $245.00 target price on the insurance provider’s stock.
Several other equities research analysts also recently issued reports on HUM. UBS AG restated a neutral rating and set a $237.00 price objective (up from $205.00) on shares of Humana in a report on Wednesday, June 28th. BidaskClub upgraded Humana from a sell rating to a hold rating in a research report on Wednesday, August 23rd. Morgan Stanley lifted their target price on Humana from $269.00 to $276.00 and gave the stock an overweight rating in a research report on Thursday, August 17th. J P Morgan Chase & Co lowered Humana from an overweight rating to a neutral rating and set a $253.00 target price for the company. in a research report on Monday. Finally, Zacks Investment Research lowered Humana from a hold rating to a sell rating in a research report on Thursday, July 27th. Eleven research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. The company presently has a consensus rating of Buy and an average price target of $251.60.
Shares of Humana (HUM) traded down 1.108% during trading on Tuesday, reaching $238.765. The company had a trading volume of 257,921 shares. The company has a market capitalization of $34.51 billion, a P/E ratio of 19.642 and a beta of 0.86. The firm has a 50-day moving average price of $247.97 and a 200-day moving average price of $235.16. Humana has a 52-week low of $165.03 and a 52-week high of $259.76.
Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, August 2nd. The insurance provider reported $3.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.08 by $0.41. Humana had a return on equity of 15.85% and a net margin of 3.37%. The company had revenue of $13.53 billion for the quarter, compared to the consensus estimate of $13.61 billion. During the same period in the previous year, the business earned $2.30 EPS. On average, analysts predict that Humana will post $11.56 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Humana Inc. (HUM) Earns “Hold” Rating from Royal Bank Of Canada” was reported by TrueBlueTribune and is the property of of TrueBlueTribune. If you are reading this story on another site, it was illegally copied and reposted in violation of US and international copyright & trademark laws. The correct version of this story can be accessed at https://www.truebluetribune.com/2017/10/13/humana-inc-hum-earns-hold-rating-from-royal-bank-of-canada.html.
The firm also recently announced a dividend, which will be paid on Monday, October 16th. Shareholders of record on Friday, September 29th will be paid a dividend of $0.40 per share. The ex-dividend date is Thursday, September 28th. Humana’s payout ratio is currently 13.06%.
In other Humana news, CEO Bruce D. Broussard sold 12,000 shares of Humana stock in a transaction on Friday, August 11th. The stock was sold at an average price of $251.88, for a total transaction of $3,022,560.00. Following the sale, the chief executive officer now owns 80,086 shares of the company’s stock, valued at approximately $20,172,061.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider William Kevin Fleming sold 3,071 shares of Humana stock in a transaction on Wednesday, August 23rd. The shares were sold at an average price of $250.98, for a total value of $770,759.58. Following the sale, the insider now directly owns 7,681 shares in the company, valued at approximately $1,927,777.38. The disclosure for this sale can be found here. Insiders have sold a total of 55,595 shares of company stock worth $14,133,706 in the last ninety days. 0.80% of the stock is owned by company insiders.
A number of institutional investors have recently made changes to their positions in the business. Eqis Capital Management Inc. raised its stake in Humana by 13.7% during the 3rd quarter. Eqis Capital Management Inc. now owns 10,747 shares of the insurance provider’s stock valued at $2,618,000 after acquiring an additional 1,295 shares in the last quarter. Achmea Investment Management B.V. raised its stake in Humana by 25.3% during the 2nd quarter. Achmea Investment Management B.V. now owns 12,637 shares of the insurance provider’s stock valued at $3,039,000 after acquiring an additional 2,551 shares in the last quarter. WFG Advisors LP raised its stake in Humana by 4.5% during the 2nd quarter. WFG Advisors LP now owns 469 shares of the insurance provider’s stock valued at $113,000 after acquiring an additional 20 shares in the last quarter. Toronto Dominion Bank raised its stake in Humana by 21.5% during the 2nd quarter. Toronto Dominion Bank now owns 48,951 shares of the insurance provider’s stock valued at $11,776,000 after acquiring an additional 8,657 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd bought a new stake in Humana during the 2nd quarter valued at $790,000. 95.12% of the stock is currently owned by hedge funds and other institutional investors.
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
Receive News & Ratings for Humana Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Humana Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.